Robert McCray, MD
Cardiovascular Disease · Chesapeake, VANPI 1477653236
Payments from drug & device makers
Across 122 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$503
- Amgen$218
- Scpharmaceuticals Inc.$205
- Astellas Pharma US Inc$136
- Sanofi-aventis U.S. LLC$129
- Pfizer$115
- plus $680 from 17 others
What the payments were for
- Food & beverage$1,985100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 33 | $503 |
| Amgen | 13 | $218 |
| Scpharmaceuticals Inc. | 10 | $205 |
| Astellas Pharma US Inc | 8 | $136 |
| Sanofi-aventis U.S. LLC | 8 | $129 |
| Pfizer | 8 | $115 |
| E.r. Squibb & Sons, L.L.C. | 7 | $109 |
| Johnson & Johnson | 5 | $81 |
| AstraZeneca | 5 | $72 |
| Philips North America LLC | 3 | $61 |
| Baxter Healthcare | 2 | $53 |
| Irhythm Technologies, Inc. | 2 | $47 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $41 |
| Portola Pharmaceuticals, LLC | 2 | $35 |
| Boehringer Ingelheim | 2 | $35 |
| Chiesi USA, Inc. | 2 | $29 |
| Lundbeck LLC | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Nuwellis, Inc. | 1 | $17 |
| Bridgebio Pharma, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $13 |
| Bardy Diagnostics, Inc. | 1 | $13 |
How this compares
$1,985 in reported general payments places this provider in the 55th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 199 | $220,737 |
| EntrestoSacubitril/Valsartan | 70 | $99,048 |
| XareltoRivaroxaban | 67 | $65,483 |
| Repatha SureclickEvolocumab | 40 | $31,987 |
| JardianceEmpagliflozin | 17 | $30,145 |
| BrilintaTicagrelor | 14 | $10,037 |
| Flecainide Acetate | 51 | $3,196 |
| Ranolazine ErRanolazine | 41 | $2,300 |
| Metoprolol Succinate | 184 | $2,243 |
| Carvedilol | 122 | $1,167 |
| Ezetimibe | 38 | $882 |
| Amlodipine Besylate | 165 | $824 |
| Warfarin Sodium | 82 | $823 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 28 | $802 |
| Rosuvastatin Calcium | 46 | $799 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $115 | $220,737199 claims |
| NovartisEntresto | $503 | $99,04870 claims |
| Johnson & JohnsonXarelto | $81 | $65,48367 claims |
| Boehringer IngelheimJardiance | $35 | $30,14517 claims |
| AstraZenecaBrilinta | $72 | $10,03714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 548 cardiovascular disease providers in Virginia.
Other cardiovascular disease in Chesapeake
- Tariq HaddadFalls Church$8M
- David LimCharlottesville$6M
- Hamid TaheriManassas$4.9M
- Philip OdonnellWinchester$4.6M
- Antonio AbbateCharlottesville$4M
- George VetrovecRichmond$2.3M
- Henry TranFalls Church$1.6M
- John SchmedtjeRoanoke$1.4M
- Jonathan LindnerCharlottesville$941K
- Christopher KramerCharlottesville$929K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.